XSpray Pharma Resubmits Dasynoc Application to FDA

XSpray Pharma Advances with FDA Resubmission

XSpray Pharma AB has officially re-submitted its new drug application to the U.S. Food and Drug Administration for its drug candidate, Dasynoc. The company anticipates a new Prescription Drug User Fee Act, or PDUFA, date to be set no later than August 2026, marking the FDA's deadline for review.

Strategic Overview and Timeline

The Swedish pharmaceutical firm confirmed that the resubmission is a strategic step to address previous regulatory requirements from the FDA. This move aligns with XSpray Pharma's established plan to launch two oncology-focused products in the U.S. market during the second half of 2026. The planned launches include Dasynoc and another drug candidate, XS003 nilotinib.

Impact on Market and Development Pipeline

This development reinforces XSpray Pharma's commercialization timeline and signals progress in its drug pipeline. Dasynoc is positioned as an alternative treatment option within the oncology sector. Successfully navigating the FDA review process is crucial for the company to meet its launch targets and establish a presence in the competitive U.S. pharmaceutical market.

Conclusion

The resubmission marks a significant milestone for XSpray Pharma as it moves closer to its goal of commercializing two key products. Market stakeholders will closely monitor the FDA's response and the official assignment of a PDUFA date. The outcome will be a key determinant of the company's growth trajectory for 2026 and beyond.

FAQ

Q: What is Dasynoc?
A: Dasynoc is XSpray Pharma's drug candidate, designed as an alternative treatment option in the field of oncology.

Q: What is the significance of the PDUFA date?
A: The PDUFA date is the deadline by which the FDA must complete its review of a new drug application, making it a critical milestone in the approval process.

Q: What are XSpray Pharma's launch plans?
A: The company plans to launch two products, Dasynoc and XS003 nilotinib, in the U.S. market during the second half of 2026.

Source: Investing.com